TH
The startup develops first-in-class drug candidates targeting Type 2 Diabetes Mellitus (T2DM) and its complications, utilizing a platform that enhances insulin sensitivity and gut microbiota composition. Their therapies aim to improve patient care and disease management for individuals suffering from T2DM.
Updated 3 months ago
Funding
$510K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops first-in-class drug candidates targeting Type 2 Diabetes Mellitus (T2DM) and its complications, utilizing a platform that enhances insulin sensitivity and gut microbiota composition. Their therapies aim to improve patient care and disease management for individuals suffering from T2DM.